---
layout: post
title: "Prospective Grant of an Exclusive Patent License: Development and Commercialization of CD33-Specific Chimeric Antigen Receptor (CAR) Therapies for CD33-Expressing Malignancies Using Natural Killer Cells (NK Cells) Transduced With Retroviral or Lentiviral Vectors"
date: 2026-02-05 19:08:06 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2021-00637
original_published: 2021-01-14 00:00:00 +0000
significance: 8.00
---

# Prospective Grant of an Exclusive Patent License: Development and Commercialization of CD33-Specific Chimeric Antigen Receptor (CAR) Therapies for CD33-Expressing Malignancies Using Natural Killer Cells (NK Cells) Transduced With Retroviral or Lentiviral Vectors

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** January 14, 2021 00:00 UTC
**Document Number:** 2021-00637

## Summary

The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Senti Bio ("Senti"), located in South San Francisco, CA.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2021/01/14/2021-00637/prospective-grant-of-an-exclusive-patent-license-development-and-commercialization-of-cd33-specific)
- API: https://www.federalregister.gov/api/v1/documents/2021-00637

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
